Source: Pharamceutical Technology

Dragonfly: Dragonfly and Gilead enter partnership for cancer therapy

Dragonfly Therapeutics has entered a clinical collaboration with Gilead Sciences to assess DF1001 plus Trodelvy for cancer indications.

Read full article »
Dragonfly's Competitors | Dragonfly's News | Dragonfly's Financials
Stay up-to-date with the latest news on Dragonfly
Est. Annual Revenue
$100K-5.0M
Est. Employees
100-250
William Haney's photo - Co-Founder & CEO of Dragonfly

Co-Founder & CEO

William Haney

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Dragonfly